U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Metastatic Hepatocellular Carcinoma

MedGen UID:
852738
•Concept ID:
C0744869
•
Neoplastic Process
Synonyms: Metastatic hepatocellular carcinoma; Metastatic liver cell carcinoma
SNOMED CT: Metastatic hepatocellular carcinoma (708973006); Metastatic liver cell carcinoma (1186612004); Metastatic hepatocellular carcinoma (1186612004)

Definition

A hepatocellular carcinoma that has spread to another anatomic site. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMetastatic Hepatocellular Carcinoma

Professional guidelines

PubMed

Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Meng R, Zhang X, Zhou T, Luo M, Qiu Y
Expert Rev Pharmacoecon Outcomes Res 2022 Oct;22(7):1079-1086. Epub 2022 May 26 doi: 10.1080/14737167.2022.2079498. PMID: 35579405
Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges.
Jiang JF, Lao YC, Yuan BH, Yin J, Liu X, Chen L, Zhong JH
Oncotarget 2017 May 16;8(20):33911-33921. doi: 10.18632/oncotarget.15411. PMID: 28430610Free PMC Article
Hepatocellular Carcinoma: Surgical Management and Evolving Therapies.
Kantor O, Baker MS
Cancer Treat Res 2016;168:165-83. doi: 10.1007/978-3-319-34244-3_8. PMID: 29206369

Recent clinical studies

Etiology

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group
Lancet 2023 Sep 30;402(10408):1133-1146. Epub 2023 Jul 24 doi: 10.1016/S0140-6736(23)00961-3. PMID: 37499670
Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
Jang YJ, Kim EJ, Kim HD, Kim KP, Ryu MH, Park SR, Choi WM, Lee D, Choi J, Shim JH, Kim KM, Lim YS, Lee HC, Ryoo BY, Yoo C
J Cancer Res Clin Oncol 2023 Aug;149(10):7547-7555. Epub 2023 Mar 27 doi: 10.1007/s00432-023-04704-3. PMID: 36971796
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group
Lancet Oncol 2021 Jul;22(7):977-990. Epub 2021 Jun 15 doi: 10.1016/S1470-2045(21)00252-7. PMID: 34143971
Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges.
Jiang JF, Lao YC, Yuan BH, Yin J, Liu X, Chen L, Zhong JH
Oncotarget 2017 May 16;8(20):33911-33921. doi: 10.18632/oncotarget.15411. PMID: 28430610Free PMC Article
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z
Lancet Oncol 2009 Jan;10(1):25-34. Epub 2008 Dec 16 doi: 10.1016/S1470-2045(08)70285-7. PMID: 19095497

Diagnosis

Establishment and characterization of a highly metastatic hepatocellular carcinoma cell line.
Huang J, Sun M, Wang M, Yu A, Zheng H, Bu C, Zhou J, Zhang Y, Qiao Y, Hu Z
Bioengineered 2024 Dec;15(1):2296775. Epub 2024 Jan 7 doi: 10.1080/21655979.2023.2296775. PMID: 38184822Free PMC Article
European Society of Organ Transplantation (ESOT) Consensus Report on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma.
Claasen MPAW, Sneiders D, Rakké YS, Adam R, Bhoori S, Cillo U, Fondevila C, Reig M, Sapisochin G, Tabrizian P, Toso C
Transpl Int 2023;36:11648. Epub 2023 Sep 14 doi: 10.3389/ti.2023.11648. PMID: 37779513Free PMC Article
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group
Lancet Oncol 2021 Jul;22(7):977-990. Epub 2021 Jun 15 doi: 10.1016/S1470-2045(21)00252-7. PMID: 34143971
Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges.
Jiang JF, Lao YC, Yuan BH, Yin J, Liu X, Chen L, Zhong JH
Oncotarget 2017 May 16;8(20):33911-33921. doi: 10.18632/oncotarget.15411. PMID: 28430610Free PMC Article
A Systematic Review of Metastatic Hepatocellular Carcinoma to the Spine.
Goodwin CR, Yanamadala V, Ruiz-Valls A, Abu-Bonsrah N, Shankar G, Sankey EW, Boone C, Clarke MJ, Bilsky M, Laufer I, Fisher C, Shin JH, Sciubba DM
World Neurosurg 2016 Jul;91:510-517.e4. Epub 2016 May 13 doi: 10.1016/j.wneu.2016.04.026. PMID: 27090971Free PMC Article

Therapy

Combined inhibition of surface CD51 and γ-secretase-mediated CD51 cleavage improves therapeutic efficacy in experimental metastatic hepatocellular carcinoma.
Cai J, Wang J, Jiang C, Ye L, He X, Huang J, Sun X, Ren Z, Lai X, Qiu Y, Wang H, Lv G, Zheng J, Lu T, Chen H, Liu Y, Chen H, Guan Y, Wang Y, Wang T, Yao J, Sui X, Kang Y, Zhang Y, Li H, Wang J, Li W, Chen G, Yang Y, Xiang AP
J Hepatol 2023 Dec;79(6):1418-1434. Epub 2023 Aug 19 doi: 10.1016/j.jhep.2023.08.007. PMID: 37604269
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group
Lancet 2023 Sep 30;402(10408):1133-1146. Epub 2023 Jul 24 doi: 10.1016/S0140-6736(23)00961-3. PMID: 37499670
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, Ying J, Lu Y, Meng Z, Pan H, Yang P, Zhang H, Chen X, Xu A, Cui C, Zhu B, Wu J, Xin X, Wang J, Shan J, Chen J, Zheng Z, Xu L, Wen X, You Z, Ren Z, Liu X, Qiu M, Wu L, Chen F
J Clin Oncol 2021 Sep 20;39(27):3002-3011. Epub 2021 Jun 29 doi: 10.1200/JCO.21.00163. PMID: 34185551Free PMC Article
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group
Lancet Oncol 2021 Jul;22(7):977-990. Epub 2021 Jun 15 doi: 10.1016/S1470-2045(21)00252-7. PMID: 34143971
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z
Lancet Oncol 2009 Jan;10(1):25-34. Epub 2008 Dec 16 doi: 10.1016/S1470-2045(08)70285-7. PMID: 19095497

Prognosis

Combined inhibition of surface CD51 and γ-secretase-mediated CD51 cleavage improves therapeutic efficacy in experimental metastatic hepatocellular carcinoma.
Cai J, Wang J, Jiang C, Ye L, He X, Huang J, Sun X, Ren Z, Lai X, Qiu Y, Wang H, Lv G, Zheng J, Lu T, Chen H, Liu Y, Chen H, Guan Y, Wang Y, Wang T, Yao J, Sui X, Kang Y, Zhang Y, Li H, Wang J, Li W, Chen G, Yang Y, Xiang AP
J Hepatol 2023 Dec;79(6):1418-1434. Epub 2023 Aug 19 doi: 10.1016/j.jhep.2023.08.007. PMID: 37604269
A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma.
Lu Y, Yang A, Quan C, Pan Y, Zhang H, Li Y, Gao C, Lu H, Wang X, Cao P, Chen H, Lu S, Zhou G
Nat Commun 2022 Aug 6;13(1):4594. doi: 10.1038/s41467-022-32283-3. PMID: 35933472Free PMC Article
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group
Lancet Oncol 2021 Jul;22(7):977-990. Epub 2021 Jun 15 doi: 10.1016/S1470-2045(21)00252-7. PMID: 34143971
Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3.
Sun H, Wang C, Hu B, Gao X, Zou T, Luo Q, Chen M, Fu Y, Sheng Y, Zhang K, Zheng Y, Ren X, Yan S, Geng Y, Yang L, Dong Q, Qin L
Signal Transduct Target Ther 2021 May 26;6(1):187. doi: 10.1038/s41392-021-00579-3. PMID: 34035222Free PMC Article
A Systematic Review of Metastatic Hepatocellular Carcinoma to the Spine.
Goodwin CR, Yanamadala V, Ruiz-Valls A, Abu-Bonsrah N, Shankar G, Sankey EW, Boone C, Clarke MJ, Bilsky M, Laufer I, Fisher C, Shin JH, Sciubba DM
World Neurosurg 2016 Jul;91:510-517.e4. Epub 2016 May 13 doi: 10.1016/j.wneu.2016.04.026. PMID: 27090971Free PMC Article

Clinical prediction guides

Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma.
Sun Y, Wu P, Zhang Z, Wang Z, Zhou K, Song M, Ji Y, Zang F, Lou L, Rao K, Wang P, Gu Y, Gu J, Lu B, Chen L, Pan X, Zhao X, Peng L, Liu D, Chen X, Wu K, Lin P, Wu L, Su Y, Du M, Hou Y, Yang X, Qiu S, Shi Y, Sun H, Zhou J, Huang X, Peng DH, Zhang L, Fan J
Cancer Cell 2024 Jan 8;42(1):135-156.e17. Epub 2023 Dec 14 doi: 10.1016/j.ccell.2023.11.010. PMID: 38101410
A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma.
Lu Y, Yang A, Quan C, Pan Y, Zhang H, Li Y, Gao C, Lu H, Wang X, Cao P, Chen H, Lu S, Zhou G
Nat Commun 2022 Aug 6;13(1):4594. doi: 10.1038/s41467-022-32283-3. PMID: 35933472Free PMC Article
Bronchial artery embolization for hemoptysis caused by metastatic hepatocellular carcinoma.
Kim S, Kim JH, Ko GY, Gwon DI, Shin JH, Yoon HK
Sci Rep 2022 Apr 28;12(1):6906. doi: 10.1038/s41598-022-10972-9. PMID: 35484185Free PMC Article
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, Ying J, Lu Y, Meng Z, Pan H, Yang P, Zhang H, Chen X, Xu A, Cui C, Zhu B, Wu J, Xin X, Wang J, Shan J, Chen J, Zheng Z, Xu L, Wen X, You Z, Ren Z, Liu X, Qiu M, Wu L, Chen F
J Clin Oncol 2021 Sep 20;39(27):3002-3011. Epub 2021 Jun 29 doi: 10.1200/JCO.21.00163. PMID: 34185551Free PMC Article
A Systematic Review of Metastatic Hepatocellular Carcinoma to the Spine.
Goodwin CR, Yanamadala V, Ruiz-Valls A, Abu-Bonsrah N, Shankar G, Sankey EW, Boone C, Clarke MJ, Bilsky M, Laufer I, Fisher C, Shin JH, Sciubba DM
World Neurosurg 2016 Jul;91:510-517.e4. Epub 2016 May 13 doi: 10.1016/j.wneu.2016.04.026. PMID: 27090971Free PMC Article

Recent systematic reviews

Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Zou J, Zhu W, Meng H, Luo P, Zhang J
Expert Rev Gastroenterol Hepatol 2019 Mar;13(3):271-279. Epub 2019 Jan 25 doi: 10.1080/17474124.2019.1570135. PMID: 30791765
A Systematic Review of Metastatic Hepatocellular Carcinoma to the Spine.
Goodwin CR, Yanamadala V, Ruiz-Valls A, Abu-Bonsrah N, Shankar G, Sankey EW, Boone C, Clarke MJ, Bilsky M, Laufer I, Fisher C, Shin JH, Sciubba DM
World Neurosurg 2016 Jul;91:510-517.e4. Epub 2016 May 13 doi: 10.1016/j.wneu.2016.04.026. PMID: 27090971Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...